Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK's Investigational Adjuvanted HPV9 Vaccine in Females
NCT05496231Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2022
- Primary completion
- Feb 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
A Phase 2 trial of GSK4106647 in cervical intraepithelial neoplasia (CIN), human papillomavirus infection, sponsored by GSK. Started Aug 2022; status: completed.
02
Drugs
GSK4106647
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on NCT05496231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05496231.